



Subt. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
HYZ-050CP2Application Number
09/412,947Applicant
AgrawalFiling Date
October 05, 1999Group Art Unit
1635

Sheet

1

OF

4

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JE</i>	4,309,404	1/5/1982	DeNeale et al.	424	21	
<i>JE</i>	4,309,406	1/5/1982	Guley et al.	424	21	
<i>JE</i>	4,556,552	12/3/1985	Porter et al.	424	32	
<i>JE</i>	4,704,295	11/3/1987	Porter et al.	427	3	
<i>JE</i>	5,220,007	12/21/1993	Cho-Chung	424	450	
<i>JE</i>	5,271,941	12/21/1993	Cho-Chung	424	450	
<i>JE</i>	5,470,967	11/28/1995	Huie et al.	536	24.3	
<i>JE</i>	5,652,355	7/29/1997	Metelev et al.	536	24.5	
<i>JE</i>	5,969,117	10/19/1999	Agrawal	536	22.1	

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>JE</i> ✓	0 490 077 A1	10/21/1991	EP	C12N 15	11		X
<i>JE</i> ✓	94/17189	8/4/1994	WO	C12N 15	54		X
<i>JE</i> ✓	94/23028	10/13/1994	WO	C12N 15	11		X
<i>JE</i> ✓	96/16976	6/6/1996	WO	CO7H 21	02		X
<i>JE</i> ✓	96/31600	10/10/1996	WO	C12N 15	11		X
<i>JE</i> ✓	97/11171	3/27/1997	WO	C12N 15	11		X

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)


<i>JE</i>	A1	Agrawal and Goodchild, "Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation." <i>Tet. Lett.</i> , Vol. 28, No. 31, pp. 3539-3542 (1987)
<i>JE</i>	A2	Agrawal and Zhang, "Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animal" In: Antisense Research and Application, S. T. Crooke, ed., Handbook of Experimental Pharmacology, Springer, Berlin, pp. 525-543 (1998)
<i>JE</i>	A3	Agrawal et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus." <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 85, pp. 7079-7083 (1988)
<i>JE</i>	A4	Agrawal et al., "Antisense oligonucleotides as antiviral agents." <i>Trends Biotechnol.</i> , Vol. 10, pp. 152-158 (1992)
<i>JE</i>	A5	Beaucage, Serge L., "Oligodeoxyribonucleotides Synthesis," <i>Meth. Mol. Biol.</i> , Vol. 20, pp. 33-61 (1993) <i>Humana Press, Totowa, N.J.</i> <i>in Protocols for Oligonucleotide Analogs.</i>
<i>JE</i>	A6	Beaucage, in Protocols for Oligonucleotides and Analogs: Synthesis and Properties Agrawal (ed.), Humana Press, Totowa, NJ, pp. 53-62 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER, initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.


duplicate
of A5
reference



Subt. For, PTO-1449		Docket Number HYZ-050CP2	Application Number 09/412,947
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)		Applicant Agrawal	
		Filing Date October 05, 1999	Group Art Unit 1635
Sheet	2	OF	4

	B1	Beebe et al. "Cyclic Nucleotides-Dependent Protein Kinases" in The Enzymes: Control by Phosphorylation, Academic Press, NY, Vol. 17, No. A, pp. 43-111 (1986)
	B2	Bergot et al. "Separation of synthetic phosphorothioate oligodeoxynucleotides from their oxygenated (phosphodiester) defect species by strong-anion-exchange high-performance liquid chromatography." <i>J. Chromatog.</i> , Vol. 559, pp. 35-42 (1992)
	B3	Buckheit et al., "Characterization of an HIV-1 Isolated Displaying an Apparent Absence of Virion-Associated Reverse Transcriptase Activity." <i>AIDS Research and Human Retroviruses</i> , Vol. 7, No. 3, pp. 295-302 (1991)
	B4	Cadd et al., "Holoenzymes of cAMP-dependent protein kinase containing the neural form of type I regulatory subunit have an increased sensitivity to cyclic nucleotides." <i>J. Biol. Chem.</i> , Vol. 265, pp. 19502-19506 (1990)
	B5	Cambell et al., "Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid." <i>Biochem. Biophys. Meth.</i> , Vol. 20, pp. 259-267 (1990)
	B6	Cheng et al., "An active twenty-amino-acid-residue peptide derived from the inhibitor protein of the cyclic AMP-dependent protein kinase." <i>Biochem J.</i> , Vol. 231, No. 3, pp. 655-661 (1985)
	B7	Cho-Chung, YS, "Hypothesis. Cyclic AMP and its receptor protein in tumor growth regulation in vivo." <i>J. Cyclic Nucleotide Res.</i> , Vol. 6, pp. 163-167 (1980)
	B8	Cho-Chung, YS, "Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy." <i>Cancer Res.</i> , Vol. 50, pp. 7093-7100 (1990)
	B9	Cho-Chung et al., <i>Curr. Opin. Thera. Patents</i> , Vol. 3, pp. 1737-1750 (1993)
	B10	Ciardiello and Tortora, "Interactions between the Epidermal Growth Factor Receptor and Type I Protein Kinase A: Biological Significance and Therapeutic Implications." <i>Clin. Cancer Res.</i> , Vol. 4, pp. 821-828 (1998)
	B11	Clegg et al., "Genetic characterization of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase" <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 85, pp. 3703-3707 (1988)
	B12	Ekanager et al., "The Separate Estimation of cAMP Intracellularly Bound to the Regulatory Subunits of Protein Kinase I and II in Glucagon-stimulated Rat Hepatocytes." <i>J. Biol. Chem.</i> , Vol. 260, pp. 3393-3401 (1985)
		Fokman Judah, "Tumor Angiogenesis." In: J. Mendelsohn et al., eds., The Molecular Basis of Cancer, pp. 206-232, Philadelphia: WB Saunders (1993)
	B14	Froehler, Brian C., "Deoxynucleoside H-Phosphonate Diester Intermediates in the Synthesis of Internucleotide Phosphate Analogues." <i>Tetrahedron Lett.</i> , Vol. 27, pp. 5575-5578 (1986)
	B15	Galbraith et al. "Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the Monkey" <i>Antisense Research and Development</i> , Vol. 4, pp. 201-206 (1994)

EXAMINER 	DATE CONSIDERED 6-14-01
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	



Subj. For. PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
HYZ-050CP2Application Number
09/412,947Applicant
AgrawalFiling Date
October 05, 1999Group Art Unit
1635

Sheet

3

OF


4

<i>See A9 on 5-19-01 IDS</i>	<i>JE</i>	C1	Goldstein et al., "Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model." <i>Clin. Cancer Res.</i> , Vol. 1, No. 11, pp. 1311-1318 (1995)
	<i>JE</i>	C2	Goldstein, John, "Bioconjugate Chemistry," <i>Bioconjugate Chem.</i>, Vol. 2, pp. 165-187 (1990)
	<i>JE</i>	C3	Henry et al. <i>Pharm. Res.</i> 11: PPDM8082 (1994)
	<i>JE</i>	C5	Iyer et al., "A Novel Nucleoside Phosphoramidite Synthon Derived From 1 <i>R</i> , 2 <i>iS</i> - Ephedrine." <i>Tetrahedron Asymmetry</i> , Vol. 6, pp. 1051-1054 (1995)
<i>B1 of 5-14-01 B2 5-19-01 IDS</i>	<i>JE</i>	C6	Kabat and Meyer (ed.), "Sequences of Proteins and Nucleic Acids," <i>Protein Sequences</i>, Vol. 1, pp. 1-125 (1972)
	<i>JE</i>	C7	Kemp et al., "Role of Multiple Basis Residues in Determining the Substrated Specificity of Cyclic AMP-dependent Protein Kinase." <i>J. Biol. Chem.</i> , Vol. 252, pp. 4888-4894 (1977)
	<i>JE</i>	C8	Krebs, Edwin, "Protein Kinases" <i>Curr. Topics Cell. Regul.</i> , Vol. 5, pp. 99-133 (1972)
	<i>JE</i>	C9	Loda et al., "Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas." <i>Nature Medicine</i> , Vol. 3, pp. 231-234 (1997)
	<i>JE</i>	C10	Lohmann and Walter, "Regulations of the Cellular and Subcellular Concentrations and Distribution of Cyclic Nucleotide-Dependent Protein Kinases." <i>Advances in Cyclic Nucleotide and Protein Phosphorylation Research</i> , Vol. 18, pp. 63-117, Raven, New York, (1984)
	<i>JE</i>	C11	Lu et al., "In vivo stability, pharmacokinetics, and metabolism of a "hybrid" oligonucleotide phosphorothioates in rats" <i>Proc. Annu. Meet. Am. Assoc. Cancer Res.</i> , Vol. 36, p. 411 (Abstract 2450) (1995)
	<i>JE</i>	C12	Mantel, "Evaluation of survival data and two new rank order statistics arising in its consideration." <i>Cancer Chem. Rep.</i> , Vol. 50, No. 3, pp. 163-170 (1966)
	<i>JE</i>	C13	Monia et al., "Evaluation of 2' -Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression." <i>Journal of Biological Chemistry</i> , Vol. 268, pp. 14514-145222 (1993)
	<i>JE</i>	C14	Nara and Fischinger, "Quantitative infectivity assay for HIV-1 and HIV-2." <i>Nature</i> , Vol. 332, pp. 469-470 (1988)
	<i>JE</i>	C15	Nesterova and Cho-Chung, "A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth." <i>Nature Med.</i> , Vol. 1, pp. 528-533 (1995)
	<i>JE</i>	C16	Nigg et al., "Cyclic-AMP-Dependent Protein Kinase Type II Is Associated with the Golgi Complex and with Centrosomes." <i>Cell</i> , Vol. 41, pp. 1039-1051 (1985)
	<i>JE</i>	C17	Øyen et al., "A unique mRNA species for a regulatory subunit of cAMP-dependent protein kinase is specifically induced in haploid germ cells." <i>FEBS Lett.</i> , Vol. 229, pp. 391-394 (1988)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Subt. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
HYZ-050CP2Application Number
09/412,947Applicant
AgrawalFiling Date
October 05, 1999Group Art Unit
1635

Sheet 4 OF 4

<i>JE</i>	D1	Padmapriya et al., "Large-Scale Synthesis, Purification, and Analysis of Oligodeoxynucleotide Phosphorothioates." <i>Antisense Res. & Dev.</i> , Vol. 4, pp. 185-199 (1994)
<i>JE</i>	D2	Pisetsky et al., "Stimulation of <i>in vitro</i> proliferation of murine lymphocytes by synthetic oligodeoxynucleotides" <i>Molecular Biology Report</i> , Vol. 18, pp. 217-221 (1993)
<i>JE</i>	D3	Remington's Pharmaceutical Sciences (18th ed.) Genarro, ed., Mack Publishing Co., Easton, PA, (1990)
<i>JE</i>	D4	Rohlf et al., "8-Cl-cAMP induces truncation and down-regulation of the RI alpha subunit and up-regulation of the RII beta subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells." <i>J. Biol. Chem.</i> , Vol. 268, pp. 5774-5782 (1993)
<i>JE</i>	D5	Roskoski, Robert, "Assays of Protein Kinase" <i>Methods Enzymol.</i> , Vol. 99, pp. 3-6 (1983)
<i>JE</i>	D6	Salomon, "Epidermal growth factor-related peptides and their receptors in human malignancies" <i>Crit. Rev. Oncol. Hematol.</i> , Vol. 19, pp. 183-232 (1995)
<i>JE</i>	D7	Slapak et al. in Harrison's Principles of Internal Medicine (Isselbacher et al., eds.) McGraw-Hill, Inc., NY, pp. 1826-1850 (1994)
<i>JE</i>	D8	Tagliaferri et al., "Reverse Transformation of Harvey Murine Sarcoma Virus-transformed NIH/3T3 Cells by Site-selective Cyclic AMP Analogs." <i>J. Biol. Chem.</i> , Vol. 263, pp. 409-416 (1988)
<i>JE</i>	D9	Tortora et al., "An antisense oligodeoxynucleotide targeted against the type II _β regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects." <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 87, pp. 705-708 (1990)
<i>JE</i>	D10	Uhler et al. "Expression of cDNAs for two isoforms of the catalytic subunit of cAMP-dependent protein kinase." <i>J. Biol. Chem.</i> , Vol. 262, pp. 15202-15207 (1987)
<i>dup</i> [REDACTED]		
<i>JE</i>	D12	Weidner, "Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors" <i>Breast Cancer Res. Treat.</i> , Vol. 36, pp. 169-180 (1995)
<i>JE</i>	D13	Yu et al., "Hybrid Oligonucleotides: Synthesis, Biophysical Properties, Stability Studies, and Biological Activity" <i>Bioorganic & Medicinal Chemistry</i> , Vol. 4, No. 10, pp. 1685-1692 (1996)
<i>JE</i>	D14	Zamecnik and Stephenson, "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide." <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 75, pp. 280-284 (1978)
<i>dup</i> [REDACTED]		
<i>JE</i>	D16	Zhao et al., "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation" <i>Biochemical Pharmacology</i> , Vol. 51., pp. 173-182 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.